Testing YntraDose before chemotherapy for advanced pancreas cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment called YntraDose, given directly into the pancreas tumor before standard chemotherapy. It is for people with locally advanced pancreatic cancer that cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of pancreas cancer called adenocarcinoma
- Your cancer is locally advanced, meaning it has not spread to other organs and cannot be removed with surgery right now
- Your tumor is at least 2.6 cm wide and has a certain size range (9 to 34 ml)
- You have not had radiation therapy for pancreas cancer before
- Your overall health allows you to walk and take care of yourself (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a new drug called YL201 against standard chemotherapy for people whose pancreatic cancer has spread and no longer responds to the usual first treatment. The goal is to see if YL201 can shrink tumors and help people live longer.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
This trial tests a new injectable treatment (NRT6008) given with standard chemotherapy for people whose pancreatic cancer cannot be removed by surgery. The goal is to see if it helps control the tumor better than chemo alone.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.